1Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med, 2001, 134: 136-151.
2Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 2000, 24: 477-491.
3Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase Ⅱ study. Am J Respir Crit Care Med, 1999, 159: 1061-1069.
4King TE Jr . Treatment advances and failures in pulmonary fibrosis. European Respiratory Society (ERS) Annual Congress, 2002 Sep 18. Sweden:Stockholm, Available from: URL: http://www.ersnet.org/2/4/2-4.asp.
5Erickelberg O, Pansky A, Koehler E, et al. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J, 2001, 15: 797-806.
6King TE Jr. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med, 2000, 342: 974-975.
7Noble P. Pathology and current treatment options of idiopathic pulmonary fibrosis. European Respiratory Society (ERS) Annual Congress, 2002 Sep 18. Sweden:Stockholm, Available from: URL: http://www.ersnet.org/2/4/2-4.asp.
8Sciavolino PJ, Lee TH, Vilcek J. Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1. J Biol Chem, 1994, 269: 21627-21634.
9Wang R, Ibarra S, Verlinshi L, et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol, 2000, 279: L143-151.
10Mason RJ, Schwarz MI, Hunninghake GW, et al. NHLBI workshop summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am J Respir Crit Care Med, 1999, 160: 1771-1777.
